August might be hot for most of the country, but the first full week of the month wasn't so hot for some stocks. Here are some of the most horrendous performers across all of health care for the past week.
Dendreon tried to spin its second-quarter financial results as positively as it could. The market wasn't buying the spin, though. Shares for the pharmaceutical company plunged 26% for the week.
The problems stem from prostate cancer drug Provenge. While second-quarter sales picked up compared with the previous quarter, they were still down 8.3% year over year. As a result, Dendreon's net loss of $0.45 per share missed the average analysts' estimate of a $0.42-per-share loss.
Management pointed to as many positives as they could, including a positive opinion from Europe's Committee for Medicinal Products for Human Use and highest-ever sales in urology. Those positives weren't enough to overcome the stark financial reality that sales for Provenge will still fall in 2013 from 2012 levels.
A miss, and two on the way
Robert Mulroy, CEO of Merrimack Pharmaceuticals , said his company was "pleased with a strong quarter of progress" in the press release announcing second-quarter results. Investors weren't as pleased. Shares fell 9% this week, with most of the drop occurring after the second-quarter update was announced.
Merrimack reported a net loss for the quarter of $0.31 per share. Analysts expected a loss of $0.28 per share. That miss only partially explained investors' disappointment. Merrimack also reported some negative news with one of its clinical studies.
The company, along with development partner Sanofi , has several studies under way for cancer drug MM-121. Merrimack said that interim review of two of those studies, one in ovarian cancer and another in wild type non-small-cell lung cancer, suggested that primary endpoints would not be met. These setbacks probably affected the stock more than the earnings miss did.
Novavax shares fell 12% for the week. Like Merrimack, the company failed to meet analysts' expectations for earnings. Also like Merrimack, there's a little more to the story than just financial results.
In the case of Novavax, part of the problem stems from questions about contractual revenue coming from its partner, BARDA. Another issue is that the company seems likely to conduct additional phase 1 trials for avian flu vaccine Matrix-M, which it picked up with the acquisition of Isconova.
Of course, reporting a 51% year-over-year decrease in revenue during the second quarter doesn't look great, either. Getting the BARDA revenue flowing in will help out on that front. Positive clinical results from vaccines in the pipeline could also help shares rebound.
Toughest road ahead
Because they're still clinical-stage companies, Merrimack and Novavax can expect downturns like they experienced this week. However, they can just as easily surge on good clinical news.
Dendreon seems to have the more difficult path. Even though the company has a product that is generating revenue, those sales continue to disappoint. The market is much more forgiving of early stage biotechs without a product on the market than it is for a company that consistently disappoints after its product launches.
While Dendreon still has some hope that sales for Provenge can grow, it's going to be a tough road ahead. I think it has the highest chance for a horrendous week to turn into a horrendous year.
You can have great weeks and horrendous weeks in the stock market. Despite these ups and downs, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article 3 Horrendous Health-Care Stocks This Week originally appeared on Fool.com.
Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool owns shares of Dendreon. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.